3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
9
Thoracic
8
Head & Neck
3
Gastrointestinal
3
Sarcoma
2
Gynecologic
2
Genitourinary
2
Other hematologic neoplasm
1
Dermatologic
1
Breast
1
Conditions
Melanoma
15
Carcinoma, Renal Cell
5
Carcinoma, Non-Small-Cell Lung
5
Carcinoma, Merkel Cell
5
Breast Neoplasms
5
Small Cell Lung Carcinoma
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Lymphoma, T-Cell, Cutaneous
3
Carcinoma, Hepatocellular
3
Stomach Neoplasms
2
Sarcoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Uveal Melanoma
1
Turcot syndrome
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Skin Neoplasms
1
Sezary Syndrome
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Interventions
pembrolizumab
40
Nivolumab
18
trametinib
13
Cyclophosphamide
13
dabrafenib
11
Vemurafenib
10
Interleukin-2
10
Ipilimumab
9
fludarabine
7
Docetaxel
7
fludarabine phosphate
6
cemiplimab
6
Paclitaxel
6
Cisplatin
6
Carboplatin
6
atezolizumab
5
Radiotherapy
5
Drug Therapy
5
Dacarbazine
5
Blood Specimen Collection
5
Biopsy
5
poly ICLC
4
binimetinib
4
Therapeutics
4
Psychiatric Rehabilitation
4
sotigalimab
3
montanide ISA 51
3
encorafenib
3
cobimetinib
3
budigalimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
durvalumab
×
Dermatologic
×
Clear all
NCT02423863
2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2
Completed
26 enrolled